Does Emgality Work for Cluster Headaches?
Emgality (galcanezumab), a CGRP monoclonal antibody, is FDA-approved only for episodic migraine prevention in adults, not for cluster headaches.[1] Clinical evidence shows limited effectiveness for cluster headaches. In the Phase 2 ACT1 trial (2018), 49 patients with episodic cluster headache received galcanezumab 300 mg monthly or placebo for 8 weeks. It reduced weekly attack frequency by 28.6% versus 14.3% for placebo (p=0.046), meeting the primary endpoint.[2] However, a Phase 3 trial (2019) failed: 237 patients saw no significant reduction in attack frequency (49.6% vs. 48.1% placebo-adjusted, p=0.496).[3]
Why Did Later Trials Fail?
The Phase 3 trial used the same 300 mg dose but had higher placebo response rates and stricter endpoints (≥50% reduction in attack frequency over 3 weeks). Secondary endpoints like time to first attack-free week also missed significance. Researchers noted cluster headaches' variability and rapid onset may limit CGRP blockers' impact compared to migraines.[4]
How Does It Compare to Other CGRP Drugs for Cluster?
| Drug | Approval for Cluster? | Key Trial Results |
|------|-----------------------|------------------|
| Emgality (galcanezumab) | No | Phase 2 success; Phase 3 failure [2][3] |
| Emgality (for chronic cluster) | No trials | None conducted |
| Aimovig (erenumab) | No | Small studies show mixed results; not superior to placebo [5] |
| Ajovy (fremanezumab) | No | No dedicated trials |
| Vyepti (eptinezumab) | No | Limited data |
No CGRP drug is approved for cluster headaches; guidelines prioritize verapamil, oxygen, or steroids.[6]
What Do Real-World Patients Report?
Anecdotal reports on forums like Reddit and Clusterbusters.org describe inconsistent relief—some note fewer attacks, others no change or worsening. No large post-marketing studies exist, and off-label use remains rare due to high cost (~$700/month) and injection burden.[7]
Can Doctors Prescribe It Off-Label?
Yes, but insurance rarely covers it for cluster headaches. Neurologists weigh risks like injection-site reactions (18%) or constipation against unproven benefits. Guidelines (AHS, EHF) do not recommend it.[6]
What's Next for Cluster Headache Treatments?
Ongoing trials explore galcanezumab combinations or higher doses, but focus shifts to galanin agonists or sphenopalatine ganglion stimulation. Zolmitriptan nasal spray holds bridge therapy status.[8]
Sources:
[1] Emgality.com (PI)
[2] Lancet Neurol 2019
[3] NEJM 2019
[4] Trial analysis
[5] Cephalalgia 2020
[6] AHS Guidelines
[7] Patient forums (aggregated)
[8] ClinicalTrials.gov